CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 773 enrolled
Drug / intervention
Treatment guided by the PCR results +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06996301
NCT06996301N/ACompleted

Clinical Validity and Utility of PCR Compared to Conventional Culture and Sensitivity Testing for the Management of Complicated Urinary Tract Infections in Adults.

Doc Lab Inc·interventional·Posted May 30, 2025·Updated Sep 11, 2025

In Brief

A clinical study evaluating Treatment guided by the PCR results and Treatment guided by the C&S results for Urinary Tract Infection Complicated and 2 related conditions. Completed, enrolled 773 participants across 6 sites.

Detailed Summary

Complicated urinary tract infections (cUTIs) often lead to the overuse of empiric antibiotics, risking inappropriate treatment and contributing to antimicrobial resistance. This randomized, multi-center, investigator-blinded clinical trial is the first global head-to-head comparison of molecular diagnostic testing (Polymerase Chain Reaction : PCR) versus conventional culture and sensitivity (C\&S) for managing cUTIs in adults. Conducted across six U.S. clinical sites, the study aimed to evaluate the clinical utility of PCR-guided treatment relative to C\&S-guided care. Eligible adult patients were randomized 1:1 into two diagnostic arms-PCR or C\&S-after providing informed consent. Urine samples were collected before randomization, tested by both methods, but clinicians remained blinded to the comparator results to avoid bias. Treatment decisions were based only on the assigned test results. Urine was collected at baseline (Day 1) and at end-of-study (Day 28). Samples were processed centrally: the PCR method (DocLab UTM 2.0) detected 28 uropathogens and 16 antibiotic resistance gene classes; C\&S testing quantified bacterial loads and assessed antimicrobial susceptibility using standard thresholds (≥10⁵ CFU/mL). The primary endpoint was the number of patients in each arm achieving a Favorable Clinical Outcome (FCl) at Day 28, defined as either: * Clinical Cure (complete symptom resolution requiring no further antibiotics), or * Clinical Improvement (partial symptom resolution without new symptoms or IV antibiotics). Secondary endpoints included: * Microbiological eradication at EOS (via C\&S and PCR). * Clinician satisfaction with diagnostic usefulness and result clarity. * Turnaround time comparison between PCR and C\&S. * Concordance analysis of test results between PCR and C\&S. * FCl rates in discordant cases, where PCR and C\&S results disagreed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsDicentra Inc.

Timeline

N/ACompletedFinished
202420252026
First PostedMay 30, 2025
Enrollment StartJul 31, 2023
Primary CompletionApr 30, 2024
Study CompletionMay 31, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 1.1 years ago

Interventions

Treatment guided by the PCR resultsother

Patients receive treatment prescribed by a blinded clinician, based solely on the PCR diagnostic results

Treatment guided by the C&S resultsother

Patients receive treatment prescribed by a blinded investigator (clinician), based solely on the C\&S diagnostic results.